The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1536
ISSUE1536
December 18, 2017
Drugs for Postmenopausal Osteoporosis
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Drugs for Postmenopausal Osteoporosis
December 18, 2017 (Issue: 1536)
Diagnosis of osteoporosis is based on the results
of bone mineral density (BMD) testing or by the
occurrence of a fragility fracture. Bone densitometry
results are generally reported in terms of standard
deviations (SD) from the mean value for...more
- DM Black and CJ Rosen. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 2016; 374:254.
- FRAX. Fracture risk assessment tool. Available at www. sheffield.ac.uk. Accessed December 7, 2017.
- Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Dietary reference intakes for calcium and vitamin D. Available at http://www.iom.edu. Accessed December 7, 2017.
- DC Bauer. Clinical practice. Calcium supplements and fracture prevention. N Engl J Med 2013; 369:1537.
- PM Camacho et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis – 2016 – executive summary. Endocr Pract 2016; 22:1111.
- A Qaseem et al. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 2017; 166:818.
- NB Watts and JE Manson. Osteoporosis and fracture risk evaluation and management: shared decision making in clinical practice. JAMA 2017; 317:253.
- US Preventive Services Task Force. Draft recommendation statement. Vitamin D, calicum, or combined supplementation for the primary prevention of fractures in communitydwelling adults: preventive medication. Available at: www.uspreventiveservicestaskforce.org. Accessed December 8, 2017.
- M Chung et al. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:827.
- A Avenell et al. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev 2014; 4:CD000227.
- MJ Bolland et al. Calcium intake and risk of fracture: systematic review. BMJ 2015; 351:h4580.
- HA Bischoff-Ferrari et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012; 367:40.
- RB Wallace et al. Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements. Am J Clin Nutr 2011; 94:270.
- K Li et al. Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC-Heidelberg). Heart 2012; 98:920.
- IR Reid. Cardiovascular effects of calcium supplements. Nutrients 2013; 5:2522.
- RL Prentice et al. Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study. Osteoporo Int 2013; 24:567.
- M Chung et al. Calcium intake and cardiovascular disease risk: an updated systematic review and meta-analysis. Ann Intern Med 2016; 165:856.
- JA Eisman et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008; 35:488.
- A once-yearly IV bisphosphonate for osteoporosis. Med Lett Drugs Ther 2007; 49:89.
- DM Black et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356:1809.
- DM Black et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012; 27:243.
- DK Wysowski and JT Chang. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 2005; 165:346.
- M Pazianas et al. Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database. J Bone Miner Res 2013; 28:455.
- FDA drug safety communication: new contraindication and updated warning on kidney impairment for Reclast (zoledronic acid). Available at www.fda.gov. Accessed December 7, 2017.
- S Fedele et al. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 2010; 123:1060.
- AA Khan et al. Case-based review of osteonecrosis of the jaw (ONJ) and application of the International Recommendations for Management from the International Task Force on ONJ. J Clin Densitom 2017; 20:8.
- J Schilcher et al. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364:1728.
- E Shane et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014; 29:1.
- LY Park-Wyllie et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305:783.
- Y Vinogradova et al. Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data. BMJ 2013; 346:f114.
- NE Morden et al. Oral bisphosphonates and upper gastrointestinal toxicity: a study of cancer and early signals of esophageal injury. Osteoporos Int 2015; 26:663.
- DM Black et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296:2927.
- Denosumab (Prolia) for postmenopausal osteoporosis. Med Lett Drugs Ther 2010; 52:81.
- SR Cummings et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756.
- HG Bone et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 2017; 5:513.
- HG Bone et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011; 96:972.
- AD Anastasilakis et al. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 2017; 32:1291.
- BZ Leder et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 2015; 386:1147.
- TD Rachner et al. Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy. Mayo Clin Proc 2013; 88:418.
- S Papapoulos et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int 2015; 26:2773.
- JS Finkelstein et al. Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab 2009; 94:2495.
- DL Kendler et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2017 November 9 (epub).
- PD Miller et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 2016; 316:722.
- Abaloparatide (Tymlos) for postmenopausal osteoporosis. Med Lett Drugs Ther 2017; 59:97.
- EB Andrews et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 2012; 27:2429.
- KE Ensrud et al. Effects of raloxifene on fracture risk in postmenopausal women: the raloxifene use for the heart trial. J Bone Miner Res 2008; 23:112.
- CJ Crandall et al. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 2014; 161:711.
- Conjugated estrogens/bazedoxifene (Duavee) for menopausal symptoms and prevention of osteoporosis. Med Lett Drugs Ther 2014; 56:33.
- JV Pinkerton et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab 2014; 99:e189.
- TJ de Villiers et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 2011; 22:567.
- JH Pickar and BS Komm. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: a review of effects on the breast. Post Reprod Health 2015; 21:112.
- JA Knopp-Sihota et al. Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis. Osteoporos Int 2012; 23:17.
- In brief: Cancer risk with salmon calcitonin. Med Lett Drugs Ther 2013; 55:29.
- KG Saag et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017; 377:1417.
- F Cosman et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 2016; 375:1532.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Postmenopausal Osteoporosis
Article code: 1536a
Article code: 1536a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.